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Plasmodium falciparum 
circumsporozoite vaccine 
immunogenicity and efficacy trial with 
natural challenge quantitation in an 
area of endemic human malaria of 
Kenya 
J.A. Sherwood*t$-/-tj-, R.S. Copelandj$ K.A. Taylor*l, K. Abokll, 
A.J. Olo~ll, J.B.O. Were*, G.T. Strickland**, D.M. Gordon??, 
W.R. Balloutt, J.D. Bales Jr$, R.A. Wirtz$$, J. Wittes@, M. Gross@, 
J.U. Quefl, S.J. CryaT, C.N. Osterllll, C.R. Roberts$ and 
J.C. SadoF** 
It has been hypothesized that antibody induced by Plasmodium falciparum 
circumsporozoite protein vaccine would be eflective against endemic human malaria. In 
a malaria endemic region of Kenya, 76 volunteers, in 38 pairs sleeping adjacently, were 
immunized with subunit circumsporozoite protein Asn-Ala-Asn-Pro tetrapeptide repeat- 
pseudomonas toxin A, or hepatitis B vaccine. After quinine and doxcycycline, volunteers 
were followed for illness daily, parasitemia weekly, antibody, T-lymphocyte responses, 
and treated tf indicated. Anopheles mosquitoes resting in houses were collected, and 
tested for P. falciparum antigen, or dissected for sporozoites and tested for blood meal 
ABO type and P. falciparum antigen. Vaccine was safe, with side-eflects similar in both 
groups, and immunogenic, engendering IgG antibody as high as 600 pug ml-‘, but did 
not increase the proportion of volunteers with T-lymphocyte responses. Estimation of P. 
falciparum challenge averaged 0.194 potentially infective Anopheles biteslvolunteerl 
day. Mosquito blood meals showed no d@erence in biting intensity between vaccine and 
control groups. Both groups had similar malaria-free survival curves, cumulative positive 
blood slides, cumulative parasites mm - 3, and numbers of parasites mm - 3 on first 
positive blood slide, during three post-vaccination observation periods. Every volunteer 
had P. falciparum parastiemia at least once. Vaccinees had 82% and controls 89oY 
incidences of symptomatic parasitemia (PzO.514, eficacy 9%, statistical power 95% 
probability of eficacy ~50%). Vaccine-induced anti-sporozoite antibody was not 
protective in this study. Within designed statistical precisions the present study is in 
agreement with ejlicacy studies in Colombia, Venezuela and Tanzania. 
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Natural antibody to sporozoite antigen increasing with 
transmission intensity and age has been interpreted as 
supporting the hypothesis that vaccine induced antibody 
would protect against P. falciparum malaria’.2. Follow- 
ing demonstration that humans could be protected from 
sporozoite challenge by subunit sporozoite vaccines 
((Asn-Ala-Asn-Pro), 5 Asn-Val-Asp-Pro),=R32, with 
relatively low levels of antibodies against the central 
repeat region of P. falciparum circumsporozoite pro- 
tein3’4 second generation vaccines were designed to elicit 
higher levels of antibody. It may be hypothesized that 
supra-normal evels of antibodies to sporozoites could 
protect, even though natural levels are not correlated 
with the prevalence of parasitemia or time to onset 
of parasitemia5. Increased T-lymphocyte responses to 
sporozoite epitopes may protect, since circurnsporozoite 
protein repeat has a T-lymphocyte epitope’j, and 
endemic adults have T-lymphocyte responses to an 
epitope of the circumsporozoite protein repeat7. Efficacy 
in an endemic population with circumsporozoite repeat 
(Asn-Ala-Asn-Pro),-tetanus toxoid is unclear’. 
Immunogenicity and small-scale efficacy trials in 
malaria naive volunteers identified R32-Toxin A vaccine 
as suitable for further evaluation’. This vaccine pro- 
duced high sporozoite antibody levels in non-immune 
volunteers, was safe, and immunogenic, nearly all 
vaccinees eroconverting”. One of eight volunteers was 
protected from challenge with laboratory infected 
mosquitoes, even though titers fell to relatively low 
levels at the time of challenge. 
This endemic field trial was performed because of 
higher and more sustained antibody levels in response to 
vaccination with circumsporozoite repeat in a malaria 
endemic” than in naive3 volunteers and because wild 
mosquitoes have’* and release13 fewer sporozoites than 
laboratoryi mosquitoes. 
MATERIALS AND METHODS 
Study site 
The study area, in western Kenya, near Lake Victoria, 
has been a site of community-based medical research 
studies’ 5 and has been described15-17. The incidence of 
P. falciparum alone or with P. malariae or P. ovale was 
98.1% between 1980 and 1983”. 
Study design 
This was a prospective, placebo-controlled, random- 
ized, paired, double-blinded, active-case-seeking study. 
P. falciparum malaria incidence has been 90%5, and 89% 
over 4 months7, therefore a vaccine 50% effective would 
give an incidence of 45% in the experimental group. In 
this instance, the number of volunteers needed in each 
group for significance of 0.05 and power of 0.95 in a 
2-tailed test is 29 19. In previous studies in this area the 
drop-out rate was 15% over 8 months5s7, 1.87% per 
month or 22.5% per 12 months. 
Recruitment, pairing, randomization, anti-malarial 
clearance, treatment and follow-up 
From a censusi7, of five villages near a clinic, an 
update was made of males between the ages of 18 and 
30 years. One hundred and twenty-seven prospective 
volunteers answered a questionnaire; 110 met criteria; 
76 volunteers were enrolled. Volunteers and household 
family members were offered free medical care during 
the study and for any potential adverse effect of vaccine 
or medicines. Inclusion criteria: male, age 18-30 years, 
in good health, willing to reside in the study area 
and participate for 12 months, use no bed nets or 
other malaria prophylaxis during the study, and 
human immunodeficiency virus-l (HIV) antibody test 
negative2’. Exclusion criteria: evidence of cardiac, 
pulmonary, renal or immunologic disease, or antibody 
to HIV. 
Volunteers were asked to pair themselves to sleep in 
the same house. Paired volunteers were assigned to two 
groups of similar ages and proportions of hemoglobin 
AS. Vaccine was randomly assigned. Houses were 
inspected to ascertain that they were the customary 
sleeping houses of the community. Reed mats provided 
uniform ceilings for mosquito resting and collection. 
Interiors were divided by a wall or curtain into separate 
sleeping areas. Every 7 days volunteers switched bed 
positions in houses. 
Volunteers were given quinine sulfate 650 mg thrice 
daily for 3 days and doxcycycline 100 mg twice daily for 
7 days, before each of the three vaccinations. After the 
last vaccination, volunteers were given quinine sulfate 
650 mg thrice daily for 3 days and doxycycline twice 
daily for 28 days to eradicate blood stage and hepatic 
stage parasites. Clinical workers observed swallowing of 
medicines. For slide-proven malaria, sulfadoxine- 
pyrimethamine (Fansidar) was prescribed and swal- 
lowed in the presence of clinic staff. Chloroquine and 
amodiaquine were not prescribed. Volunteers were 
advised to avoid chloroquine and amodioquine, avail- 
able without prescription, and obtain medicines only 
from the study clinic. 
Follow-up was carried out for 12 months, 6 months 
after the last vaccination. Each morning, a clinical 
worker asked if the volunteer felt sick, took the axillary 
temperature and asked of any medicine taken. Symp- 
toms of malaria were considered to be: fever; chills; 
sweats; headache; cough; or diarrhea. If the volunteer 
felt ill with a symptom of malaria, then a blood slide was 
made. If the volunteer was moderately ill or worse, he 
was taken to the clinic by the clinical worker for history 
and physical examination and tests including malaria 
blood slide read in the clinic. Symptomatic malaria was 
defined as the presence of one or more of the above 
symptoms plus a blood slide positive for P. falciparum. 
Volunteers were given treatment for malaria if they had 
both a symptom consistent with malaria and a positive 
blood slide. After each vaccination, volunteers wrote 
down side-effects. 
Vaccine 
The experimental vaccine was recombinant (Asn-Ala- 
Asn-Pro, 5 Asn-Val-Asp-Pro),-Leu-Arg (R32LR)*“** 
covalently linked to purified Pseudomonas aeruginosa 
toxin A 9. Each dose consisted of R32LR peptide 
(175 pug), and toxin A (225 pg)” or recombinant 
hepatitis B vaccine (Energix B, SmithKline Beecham) 
control. Malaria (Swiss Serum and Vaccine Institute) 
and hepatitis vaccines were sent separately to Kenya. 
Vaccines were kept and transported at +4”C, in the dark, 
until use. 
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Day 
Figure 1 Study intervals. The expected prepatent period after 
clearance, or prophylaxis, is 14 days 
Clinical parasitology, pharmacology, hematology and 
chemistry 
Scheduled blood slides, in duplicate, were made every 
7 days23 from 2 weeks before until 52 weeks after the 
first vaccination and the number of parasites mm ~ 3 was 
determined. Symptomatic blood slides were examined at 
the clinic24. For a slide to be considered positive, at least 
five asexual stage parasites had to be seen. These slides 
were later confirmed by others in a laboratory and 
results returned to the clinic. If a slide was read as 
negative in the clinic and later found to be positive, the 
volunteer was treated. There were no slides read as 
positive in the clinic that were negative on confirmation. 
Unless otherwise stated, parasitemia refers only to P. 
falciparum, and not P. malariae or P. ovale. The tabula- 
tion of blood slides for the purpose of vaccine efficacy 
was begun 14 days after the day of completion of 
doxycycline administration (not with the day after the 
completion of immunization), to avoid including any 
recrudescent parasites. Thus, observation periods 1 and 
2 began 14 days after each of the first two vaccines were 
given (Figure 1 and Figure 4a,b), and observation period 
3 began 60 days after the third vaccine was given (study 
day 230, Figure 1 and Figure 4~). 
Serum doxycycline was assayed by reverse phase 
high-pressure liquid chromatography on samples from 
the 9th, 10th or 1 lth day of prophylaxis . Urine 
was collected every 4 weeks, frozen and analyzed for 
aminoquinolines26, 7.
Clinical hematology, urinalysis and chemistry tests 
were performed at initial screening, monthly for 12 
months and when clinically indicated. 
Humoral and cellular immunology 
Levels of anti-P. falciparum circumsporozoite (CS) 
antibody were determined by enzyme-linked immuno- 
sorbent assay (ELISA)28 with capture antigen R32LR. 
Standard sera containing 9.8 pug of IgG antibody per ml, 
specific to R32 from a previously vaccinated volun- 
teer3,29 and test sera, gave co-parallel curves of absorb- 
ance vs concentration when tested against R32LR3’. 
Positive was defined as the mean plus 3 S.D. of non- 
immune sera without exposure to malaria. Rise in titer 
was defined as a level 3 S.D. above the pre- 
immunization level for that individual. Immunofluores- 
cent assay for antibody to sporozoites was performed 
before the first and after the third vaccination’ ‘. 
Lymphocyte proliferation was performed 4-8 days 
before the first vaccination, 1 month before and 
immediately before the third vaccination, and 1 month, 
2 months and 6 months after the third vaccination7. 
Entomological background and measurement 
The Anopheles abundance of the study area has been 
described3 -33. Over 33 months, An. gambiae sensu latu 
and An. funestus comprised 90% and IO%, respectively, 
of human-biting Anopheles, and mean daily man-biting 
rates for An. gambiae s.1. and An. jiinestus were 3.3 and 
0.6, respectively32. In this area, sporozoite rates by 
salivary gland dissection were 6.2% 4-13.10h32 for An. 
gambiae, and 4.9%32 for An. funestus. Sporozoite rates 
by ELISA of undissected head and thorax samples were 
15.1% and 14.2%, respectively, for An. gambiae s.1. and 
for An. funestus35, 
for these species33. 
and, in a nearby site 8.2% and 6.1% 
The threshold of ELISA sensitivity 
is about 125 sporozoites per mosquito36. Sporozoite 
burdens in East Africa for An. gambiae and An. funestus, 
were reported to be 20004000 per salivary gland37. In 
western Kenya A. gambiae had a Beometric mean of 962 
and A. funestus 874 sporozoites 2. In western Kenya, 
86.6% of naturally infected An. gambiae transmitted, 
into sucrose or blood, a geometric mean of 3.84 sporo- 
zoites (range l-34), about 3% of the total sporozoites in 
salivary glands13. In contrast, laboratory reared An. 
gambiae contained 808-13905 sporozoites, and 44.1% of 
infected laboratory An. gambiae transmitted a geometric 
mean of 4.5 (maximum 369) sporozoites in vitro, with 
which sporozoite loads were not a predictor of the 
number of sporozoites ejected14. The entomological 
inoculation rate (EIR), calculated as the monthly man 
biting rate times the sporozoite rate”‘, or the average 
number of potentially infective Anopheles bites in a 
period of time, was during a previous study in Saradidi, 
237 per year inside houses, and 190 per year outside 
houses32. The calculated time to inoculation exposure, 
to experience one potentially infective bite, is l/EIR, for 
Saradidi, inside houses, 1.5 nights32. 
Six mornings per week, a 0.5 h collection of indoor 
resting mosquitoes was made by volunteers in the 
houses. One morning per week, experienced entomology 
workers made the collections. Mosquitoes were 
identified to species, and examined for the presence of 
blood. Four days per week, Anopheles were killed, 
desiccated and mosquito thoraces were tested later 
for P. falciparum antigen, by ELISA3’. Three days 
per week, mos3guitoes alivary glands were dissected 
for sporozoites , which were tested by ELISA for P. 
falciparum antigen3’ and mosquito blood meals were 
typed for blood groups A, B and 04’. Group 0 blood 
cells were detected by agglutination in the presence of 
lectin H (American Dade, Miami, FL). Mosquitoes were 
determined to have fed on a volunteer when the blood 
type of the blood meal was the same as the blood type of 
the volunteer, in those pairs of volunteers with differing 
blood types. Blood meal host origin was determined 
by ELISA for human or cow immunoglobulin4’. In 
a previous study, of A. gambiae s.1. and A. funestus 
collected in houses in Saradidi, 100% of blood meals 
were human or cow 4’ At the conclusion of the obser- . 
vation period (16 May 1991) 119 pyrethrum-spray-catch 
collections39 were made in volunteer’s houses, immedi- 
ately following collections by volunteers. These supple- 
mental collections were done to derive an estimate of the 
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Table 1 Age and erythrocyte characteristics of vaccine and control volunteer groups in a PkSmodkm~ fakiparum circumsporozoite Vaccine 
immunogenicity and efficacy trial 
Study groups African groups 
Vaccine Control Total Kenyans” American? 
(No.) (No.) (No.) 
irAzean (SE.)” 38 20.6 0.53 79%100% z.2 30 0.45 79%100% 76 60 79% 100% 
HbAS’ 5 13% 6 16% 11 14% 28% (Foy, 1982) 8% (Bunn, 1991) 
HbAS 26% (Allison, 1954) 
A’. 13 34% 6 16% 19 25% 39% (Giblett, 1991) 
AEJ’ 3 8% 4 11% 7 9% 4% (Giblett, 1991) 
;.. 7 15 39% 18 10 8 26% 47 33 17 22% 43 50% 17 (Giblett, 1991) 
Rh(D) Pos. 38 100% 37 97% 75 99% 95+% [Giblett, 1991) 
Rh(D) Neg. 0 0% 0 0% 0 0% 
GGPDNormal”’ 35 92% 33 87% 68 89% 72% (Allison, 1960) 
GGPDDeficient”’ 3 8% 5 13% 8 11% 28% (Allison, 1960) 
‘,+0.077, kO.7816, d.f. =I. “x2=3.524, EO.3188, d.f.=3. ***x2=0.559, fk0.4547, d.f.=l_ Probability distribution 2=0.31577, 60.40. Wifcoxon’s 
rankino/Mann-Whitnev, z=-0.603, -0.7257. “Luo people of same study area of Kenya. bAmericans of African descent. ‘(Mean Of VaCCitle 
group-1 S.E.)s(mean of control group +l SE.) 
percentage of total indoor resting mosquitoes that were 
obtained on average during morning aspiration 
collections by volunteers. No vector control methods 
were exercised in the area during the present vaccine 
study. 
Statistical analysis 
Efficacy was calculated using the formula I=1 - 
(1,/1,), where &incidence of symptomatic parasitemia, 
I,=incidence in the vaccine group, and IrEincidence in 
the control group. Analysis of variation, x2, correlation 
coefficient, Fisher’s exact test, Kaplan-Meier survival 
curve with log-rank test, and Student’s t-test were used. 
Statistical calculations were determined with the assist- 
ance of StatView 5 12+ TM (Brainpower, Inc., Calabasas, 
California, 1986). 
RESULTS 
Study population and follow up 
Age means were similar for the vaccine and control 
groups (Table I). The distribution of sickle trait was 
similar between the study population and the general 
population4244 and between the vaccine and control 
groups. There was no significant difference between the 
study population and a previously reported distribution 
of ABO blood types in this population of western 
Kenya4’. There was no significant difference between 
vaccine and control groups in distribution of ABO 
blood types. The prevalence of glucose-6-phosphatase 
dehydrogenase deficiency was similar between the 
study population and the general population46. There 
was no significant difference between vaccine and 
control groups in prevalence of glucose-6-phosphatase 
dehydrogenase deficiency (Table 1). 
There was no significant difference in volunteer par- 
ticipation between the vaccine and control groups 
(P>O.25, log rank test). Sixty-nine of 76 volunteers 
completed the study on day 367. All who left did so for 
personal reasons: to further their education or seek 
employment away from the study area. 
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Safety and adverse reactions 
There were no serious adverse reactions to the 
vaccines or medicines. Adverse reactions to vaccines 
were few in number, mild in intensity, and brief in 
duration in both vaccine and control groups. There were 
no adverse reactions manifest by the clinical hematology 
or chemistry tests. 
Humoral and cellular immunology 
Among those receiving hepatitis vaccine control, 4 of 
38 volunteers (10%) had an antibody rise to R32LR 3 
S.D. above the arithmetic mean. Among those receiving 
malaria vaccine, 73% (28 of 38) had an antibody rise to 
R32 3 S.D. above pre-immunization. The geometric 
mean titers for the malaria group increased after each of 
the vaccinations and fell during the interim (Table 2, 
Figure 2). The geometric mean titers for the control 
group did not change (Figure 2). 
Among those receiving malaria vaccine there were 
three patterns of antibody response: no increase, an 
increase with a drop toward baseline, and a sustained 
increase. Those not responding had lower pre- 
vaccination levels, and those responding had higher 
pre-vaccination levels, in agreement with the previous 
vaccine study showing greater response in those with 
higher natural levels”. In most, the third vaccination did 
not increase antibody levels beyond that achieved by the 
first or second vaccinations. The highest antibody level 
achieved was 600 pg ml- ’ . Four of 38 volunteers (10%) 
receiving malaria vaccine had peak levels in this range. 
Among controls, some had low levels of antibody, 
unchanged during the course of the study, and some had 
higher levels, also unchanged. 
There was an association between increase in sporo- 
zoite immunofluorescence score with increase in 
antibody by ELISA (n=14) and no increase in 
immunofluorescence with no increase in antibody by 
ELISA (n=9), among those receiving malaria vaccine 
(n=33) (Pl+P2=0.002, Fisher’s exact test), indicating 
peptide vaccine increased antibody to natural sporo- 
zoites, although a subset (~10) had no increase in 
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Table 2 Anti-circumsporozoite antibody levels of vaccine and control volunteer groups in a Pktsmodium falciparum malaria vaccine trial 
Time (weeks) 
Vaccine 
Mean” 
(mcg ml-‘) 
Minimum Maximum 
(mcg ml-‘) (mcg ml-‘) 
Control 
1 SD. Mean= Minimum Maximum 1 S.D. 
(mcg ml-‘) (mcg ml-‘) (mcg ml-‘) (mcg ml-‘) (mcg ml-‘) 
0.0 5.3 0.3 23.0 4.4 6.9 0.4 73.9 12.5 
4.0 63.4 3.3 66.2 129.0 9.5 0.4 45.8 10.5 
8.0 52.5 4.6 500.0 94.2 12.8 1.2 117.1 22.1 
12.0 135.6 7.2 3200.0 521.2 11.3 0.7 75.4 14.3 
16.0 41.8 3.0 298.2 65.4 9.0 0.6 72.3 12.8 
20.0 42.7 3.5 327.0 61.2 11.3 0.4 75.5 14.9 
24.0 37.1 4.7 373.1 66.3 9.0 0.3 55.8 11.8 
28.0 50.8 2.0 285.4 58.0 8.1 47.8 9.8 
34.0 43.2 4.6 273.3 62.6 8.3 
::: 
29.2 7.8 
40.0 27.1 4.2 167.4 31.9 10.0 0.4 50.4 11.5 
44.0 23.4 2.8 170.9 31.8 6.7 0.4 27.7 7.3 
48.0 31.1 3.2 217.9 50.5 7.2 0.6 29.0 7.3 
52.0 23.7 3.8 190.1 34.5 8.2 0.7 31.3 8.0 
“Geometric mean 
-4 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 
Time (Weeks) 
Figure 2 Geometric mean antibody levels for vaccine and control 
groups. At week 0 there was no significant difference between 
vaccine and control groups in antibody levels (E0.417, analysis 
of variance). From 4 to 52 weeks there were significant differ- 
ences between vaccine and control groups in antibody levels 
(EO.OOl -0.021, analysis of variance) 
immunofluoresence with an increase in antibody by 
ELISA. 
Lymphocyte responses to R32LR were determined in 
the 11th or 12th month of the study, using fresh, 
non-cryopreserved, lymphocytes. Results were available 
on 52 of 76 volunteers (68%), four of whom had positive 
responses. Two were from the control group, and two 
from the vaccine group. Among these four volunteers, 
there was no association between lymphocyte response 
and post vaccination antibody level. Among all volun- 
teers, there was no association between lymphocyte 
response and mean change in antibody level after each 
of the three vaccinations (P=O.964, 0.820. 0.870, 
ANOVA). The malaria vaccine group did not have an 
increase in the proportion of volunteers responding to 
the antigen as a T-lymphocyte epitope, in comparison 
with the placebo group. There was no correlation 
between age and stimulation index at end of study 
(r= - 0.055, n=52). T-lymphocyte responses to R32LR 
were assayed in the 1 week before the first vaccination, 
using fresh lymphocytes. Technical difficulty prevented 
completion of the pre-vaccination assay. 
Entomology and parasitologic challenge 
From May 1990 to May 1991, 10.9% of 18138 desic- 
cated Anopheles females were positive for P. falciparum 
antigen by ELISA. Of these, A. gambiae comprised 
66.5%, A. funestus 32.1% and A. arabiensis 1.4%. 7.75% 
1.2, 0 
House number 
Figure 3 Infected Anopheles per day per house. Average of I? 
falciparum antigen positives by enzyme-linked immunosorbent 
assay of dried thoraces 
of 7842 Anopheles females were P. falciparum sporo- 
zoite positive, by ELISA, after salivary gland dissec- 
tions. Therefore, 71.1% of ELISA-positive desiccated 
Anopheles were potentially infective (i.e. had P. 
falciparum sporozoites in salivary glands). Plasmodial 
circumsporozoite antigen exists in anophelene gut, 
thorax, and salivary glands during the structural devel- 
opment of the incipient sporozoite, before and possibly 
after, the sporozoite is functionally infective. The pres- 
ence of antigen alone, in thorax or in salivary gland, by 
ELISA, does not equate to infectivity. Furthermore, if 
~125 sporozoites per mosquito are present, the ELISA 
may be negative, being below the ELISA test threshold. 
Visual dissection for the presence of sporozoites was 
performed and this material tested for P. falciparum 
circumsporozoite antigen by ELISA. 
For desiccated mosquitoes, the total number of P. 
falciparum ELISA-positive Anopheles caught was 1971. 
The calculated average of infected Anopheles collected 
per volunteer was 0.137 per day. The average number of 
infected Anopheles captured per day among the study 
houses ranged from 0.02 to 1.18 (Figure 3). The mean, 
minimum and maximum number of infected Anopheles 
per house per day varied for each of the three 
observation periods (Table 3). 
Of 18 138 mosquitoes 63.2% blood fed by visual 
inspection. Of 4029 blood-fed mosquitoes for which 
blood was typed, 94.3% matched the blood type of one 
of the volunteers in the house in which the mosquito was 
caught, suggesting that ingress of blood fed mosquitoes 
from the outside was minimal. Twenty-eight of the 38 
houses contained volunteers with different blood types. 
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Table 3 Number of Plasmodium falciparum sporozoite-containing mosquitos per house per day in a malaria vaccine immunogenicity and 
efficacy trial 
Observation perioda Number of housesb Mean 1 S.D. Median Minimum Maximum 
1 38 0.469 0.426 0.383 0.000 2.083 
5 :; 0.090 241 0.126 272 0.041 127 0.000 0.640 1 315
=?=l Jun to 1 Jul; 2=27 Jul to 22 Ott; 3=31 Dee to 17 May. bn=Number of houses; some volunteers moved to new houses 
Table 4 Symptomatic malaria in vaccine and control groups in a Plasmodium falciparum malaria vaccine trial 
Number of volunteers having symptomatic malaria Number of occurrences of symptomatic malaria 
Vaccine Control Vaccine Control 
Observation period n No. % n No. % pa No. No. P 
1 38 
25 ;3 
24 38 11 29 0.795 11 12 0.384 
: 34 8 74 61 :; 22 30 86 59 0.338 8 8 56 39 44 65 0.250 61
1+2+3 38 31 a2 38 34 a9 0.514 106 121 0.343 
“x2 with continuity correction. bPaired, l-tailed f-test 
There was a significant positive correlation between the 
vaccine and control group pairs in numbers of blood fed 
Anopheles containing blood of the same type as a 
volunteer in a house (r2=0.50, P~O.001). There was no 
difference between vaccine and control groups in the 
number of blood meals from a sporozoite-positive 
Anopheles associated with individual volunteers (paired 
t-test, t=0.68, d.J=24, P=O.50). 
Four parameters were used to estimate total malaria 
challenge on volunteers. A=Proportion potentially infec- 
tive of desiccated ELISA-positive Anopheles=0.711. 
B=Proportion of blood fed Anopheles of the total 
collection=0.632. C=Average number of infected desic- 
cated Anopheles collected per volunteer per day through- 
out entire study=0.137. D=Number of times greater the 
pyrethrum spray catch (PSC) collections were than the 
accompanying aspiration collections by volunteers 
(ACV); on average=2.149. PSC collections and ACV 
were significantly correlated (loglO(PSC+1)=0.52062 x 
loglO(ACV+1)+0.74362; ?=0.351, P<O.OOl). 
Estimate of total challenge=A x B x (C+(D x C))= 
0.711 x 0.632 x (0.137+(2.149 x 0.137))=0.194 poten- 
tially infective bites per volunteer per day, or one 
infective bite every 5.2 days. 
There was no significant difference in the distribution 
of P. falciparum sporozoite-infected mosquitoes per 
house among the blood types 0, A, B and AB for 
vaccine (P=O.597) or control (PzO.565, ANOVA). There 
was no significant difference in the distribution of P. 
falciparum sporozoite-infected mosquitoes with match- 
ing blood type per volunteer among the blood types 0, 
A, B and AB for vaccine (P=O.384) or control (P=O.381, 
ANOVA). 
Antimalarial pharmacology 
Serum doxycycline levels ranged in the vaccine group 
(n=34) from 0.196 to 2.975 pg ml- ’ (mean f 1 S.D. 
=0.797 f 0.555 ,ug ml- ‘), and in the control group 
(n=35) from 0.145 to 2.686 (mean& 1 S.D.= 
0.795 f 0.606 ,ug ml- ‘), between expected published 
peak (5 pug ml - ‘) and trough (1 pug ml - ‘) levels47. There 
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were no positive blood slides during the 14 days follow- 
ing the last dose of doxycycline, the expected prepatent 
period, had an infective bite been received on the first 
day following cessation of doxycycline. Fifteen of 78 
volunteers, each on only one occasion, had a positive 
urine test for aminoquinoline, indicating compliance 
(1.6% of a possible 912 occasions) in taking only those 
medicines prescribed in the clinic, not chloroquine or 
amodiaquine available commercially. 
Clinical and parasitological outcome 
During the three postvaccination observation periods, 
the number of volunteers who developed symptomatic 
malaria in the vaccine group and control groups were 
comparable, and there were no significant differences by 
x2 analysis (Table 4). The number of occurrences of 
symptomatic malaria during each of the three post- 
vaccination observation periods in the vaccine and con- 
trol groups were comparable, and there were no 
significant differences by paired t-test (Table 4). Efficacy 
was calculated according to the formula I=1 - (I,/ 
I,)=1 - (31/38)=0.09=9% . The mean number of fever 
occurrences from any cause, defined as a temperature 3 
S.D. above the mean, was 1.3 (range O-5, n=38) for the 
vaccine group and 1.7 (range O-5, n=36) for the control 
group. There was no significant difference between the 
two groups of paired volunteers in the number of fever 
occurrences (paired 2-tailed r-test, t= - 1.247, dj=35, 
P=O.2208). 
None of the volunteers died during the study. None of 
the volunteers had severe malaria (defined as a positive 
blood slide for malaria with seizure, loss of conscious- 
ness, or hypotension (blood pressure ~80 systolic), 
cerebral malaria (defined as a positive blood slide with 
sustained coma)), a seizure, loss of consciousness, or 
change in mental status. 
All volunteers had at least 1 positive blood slide for P. 
falciparum during each of the three observation periods 
after each of the three vaccinations, except 1 vaccine and 
1 control in the first observation period (Figure da), both 
of whom had positive slides at the next clinic visit for 
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Figure 4 Kaplan-Meier actuarial curves. The tabulation of blood 
slides for the purpose of vaccine efficacy was begun 14 days after 
the day of completion of doxycycline administration (not with the day 
after the completion of immunization), to avoid including any recru- 
descent parasites. Thus, observation periods 1 and 2 began 14 days 
after each of the first two vaccines were given (study days 14 and 
70, see Fig. 1). Observation period 3 began 14+28=42 days after the 
third vaccine was given (study day 230, see Fig. 1). (a) First 
observation period. Log rank t=O.O3169, E-0.25, not significant. (b) 
Second observation period. Log rank r’=O.5585, 60.25, not signifi- 
cant. (c) Third observation period. Log rank r’=O.6629, 130.25, not 
significant 
the second vaccination. The highest P. falciparum para- 
sitemia in any volunteer was 63054 mm - 3. Survival 
curves for the proportion of volunteers free of P. 
falciparum on blood slide after the first, second and third 
vaccinations showed no difference between the vaccine 
and control groups by log rank test (Figure 4a-c). Blood 
slide results for the two groups of paired volunteers in 
the three observation periods are show in Table 5. There 
was no significant difference in the mean number of days 
until the first positive slide (patency), the total number 
of positive slides, the cumulative number of P. falci- 
parum mm - 3 (parasite densities), or mean number of P. 
falciparum mm - 3 on first positive blood slide. Twenty- 
eight (36.8%) of 76 volunteers had P. malariae alone or 
mixed parasitemia for a total of 61 times. Twenty-two 
(28.9%) of 76 volunteers had P. ovale alone or mixed 
parasitemia for a total of 29 times. The prevalences of P. 
falciparum, P. malariae and P. ovale are shown (Table 6). 
There was no significant correlation between antibody 
level at weeks 0, 8, 12, 16, 20, 24, 28, 34, 40, 44, 48 and 
52, or the mean over weeks O-52 or 34-52, or the change 
in antibody level from weeks O-4, 8-12 or 24-28, and 
time in days to first positive blood slide, cumulative 
number of positive blood slides, or cumulative number 
of parasites mm - 3 during the third observation period 
from weeks 34 to 52. Correlation between mean anti- 
body levels over weeks O-52 and number of days to first 
positive blood slide was rE0.3. 
There was no difference between volunteers with and 
without T-lymphocyte responses in time to first positive 
slide, total number of positive slides or cumulative 
parasitemia. 
DISCUSSION 
This field study was designed to determine the safety and 
efficacy of a recombinant alum adjuvanted subunit 
vaccine which induces antibodies against the repeat 
region of the P. falciparum circumsporozoite protein, in 
a malaria-experienced population. This vaccine was 
safe, with a rate of side-effects comparable to that of 
recombinant hepatitis B vaccine. 
The vaccine induced high levels of antibody in a 
subpopulation, higher than seen previously in non- 
immune or in semi-immune volunteers. In this endemic 
population, responders to this vaccine had higher pre- 
immunization natural antibody levels than non- 
responders, as was observed in a similar population no 
longer living in a malaria endemic area”. Antibody 
levels of vaccines decreased gradually over 12 months. 
There was an association between having an increase in 
antibody by ELISA and immunofluoresence, indicating 
reaction with native sporozoites, but there remained a 
subset (10 volunteers) who had antibody by ELISA but 
not by immunofluoresence. In volunteers immunized 
with (NANP)3-tetanus toxoid or recombinant R32tet32, 
although there was a correlation between level of IgG in 
protected human volunteers and inhibition of sporozoite 
invasion of cultured HepG2A-16 hepatoma cells, IgG 
from protected human volunteers did not block sporo- 
zoite invasion of human hepatocytes4’. Sporozoites can 
develop into hepatic schizonts in the presence of anti- 
body to R3249. High levels of antibodies reacting with 
sporozoites by immunofluorescence inhibit entry and 
development of sporozoites in hepatocyte culture by 
only 82-88% and have been found in the presence of 
blood stage P. falciparum infection, suggesting that a 
single antigen vaccine may not be adequate5’. Mouse 
antibody against the R32 recombinant peptide has a 
delayed inhibitory effect on development of sporozoites 
in liver cells49. Repeat epitopes may induce a distract- 
ing B-l 
y” body5’, 2. 
phocyte production of non-protective anti- 
In the present study the level of antibody did 
not correlate with the number of positive slides, time to 
onset of parasitemia or total burden of parasites. 
The vaccine did not increase the small proportion 
mounting a T-lymphocyte response. The present result 
is consistent with a report that NANP repeat is a 
T-lymphocyte epitope on the circumsporozoite protein6, 
but recognized by only a portion of the population (4 
of 52=7.7%), in agreement with previous results from 
the same area (2 of 28=7.1°h)7. The repeat region is 
conserved among widely separated regions53. Such 
conservation may reflect the low frequency of individ- 
uals whose T-lymphocytes recognize the repeat. Poly- 
morphisms in T-lymphocyte epitopes lie outside the 
repeat region 54s5 Although exposure to sporozoites . 
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Table 5 Time to first parasitemia, number of episodes of parasitemia, aggregate numbers of parasites, and parasite density in first episode of 
parasitemia in vacccine and control volunteer groups in a Plasmodium falciparum malaria vaccine trial 
Vaccine 
Observation period n Mean Min 
No. days to first positive blood slide for F! falciparum 
: 37 8 15 4 4 
3 34 26 2 
No. positive blood slides for F! falciparum 
1 38 2 0 
2 38 5 0 
3 34 7 1 
No. P. falciparum mrne3 
1 38 1470 0 
2 38 1441 0 
3 34 4350 58 
No. P: falciparum mm-3 on first positive blood slide 
: 36 7 297 155 2 1
3 34 582 2 
BPaired, 1 -tailed f-test 
Max 
25 69
a5 
4 
12 
la 
22687 
27918 
36802 
6405 4971
8080 
Control 
n Mean Min Max pa 
37 :; 4 25 73 0.366 198
35 23 4 71 0.252 
38 2.2 0 4 0.452 
37 5.4 1 13 0.399 
35 6.4 1 14 0.139 
38 794 0 6118 0.169 
37 1471 2 13757 0.496 
35 6217 3 62049 0.214 
z; 390 169.7 : 5659 1705 0.249 183
35 791 3 13015 0.332 
Table 6 Prevalence of Plasmodium falciparum, Plasmodium malariae and Plasmodium ova/e in vaccine and control volunteer groups in a 
malaria vaccine trial 
Species 
Vaccine Control Combined 
n % n % n % 
F! falciparum 604 93.5 
I? malariae 14 2.2 
I? ova/e 4 0.6 
I? falciparumi P malariae 14 2.2 
F1 falciparum+P ova/e 9 1.4 
F! malariae+P. ova/e 0 0.0 
I? falciparum+P malariae+i? ova/e 1 0.2 
Total F! falciparum any 628 97.2 
Total 646 100.0 
571 
13 
a 
9 
z 
0 
585 
606 
94.2 
2.1 
1.3 
1.5 
0.8 
0.0 
0.0 
96.5 
100.0 
1175 
27 
12 
23 
14 
0 
:213 
1252 
93.8 
2.2 
1 .o 
1.8 
1.1 
0.0 
0.1 
96.9 
100.0 
boosts immunity initiated by a sporozoite vaccine in 
mice56, exposure to natural sporozoites after the third 
vaccination did not appear to increase the proportion of 
volunteers with a T-lymphocyte response. P. berghei 
sporozoites do not prime mouse T-lymphocytes for 
circumsporozoite epitopes5’, which appears to be the 
case for P. falciparum sporozoites in humans, based on 
the 7% prevalence of T-lymphocyte response to R32LR 
in this study. 
This vaccine did not protect this population against 
malaria. All volunteers acquired parasitemia. Vaccine 
and control groups had the same malaria-free survival 
curves, number of positive slides for malaria, parasite 
densities. This vaccine had protected 1 of 8 non-immune 
American vaccinees from sporozoite challenge, using 5 
laboratory infected An. stephensi mosquitoes, at least 
50% of mosquitoes infected with at least 2+(10-100 
sporozoites per gland)“, with a correlation between 
immunofluorescence and antibody by ELISA”. With 
this vaccine there had been no correlation between 
serum inhibition of sporozoite invasion of hepatoma 
cells with human protection”. Close follow-up and 
early treatment may have precluded the development of 
severe malaria, so a vaccine effect on this could not be 
determined. 
This study provides an indirect comparison of exper- 
imentally infected laboratory mosquitoes with natural 
field exposure. The entomological challenge in numbers 
of P. falciparum sporozoite-infected mosquitoes per 
volunteer was 0.194 per day, an average of one infec- 
tious bite every 5.2 days. Five laboratory infected 
mosquitoes at once have been used in laboratory efficacy 
studies3,4%‘0. It may be thought that the malaria chal- 
lenge is high in western Kenya, and too severe a test 
for vaccine efficacy. However, in this study, there was 
a 70-fold range in challenge, 3.5-245 P. falciparum 
infected mosquitoes collected per house. It was import- 
ant to conclude that absence of malaria was not due to 
absence of infected mosquitoes. 
The SPf66 vaccine has the sequence CGDELEAETQ 
NWAAP NANP YSLFQKEKMVLP NANP PANKK 
NAG (NANP=Asn-Ala-Asn-Pro)58. Immunization of 
rabbits with SPf66 induced antibody to (Asn-Ala-Asn- 
Pro)40, but not of monkeys nor human volunteers5*. 
SPf66 has been reported 33.6% effective (95% confi- 
dence interval l&845.7%), against a first episode of 
endemic malaria, with blood slides made every 4-8 
weeks, in a semi-immune human population in 
Colombia59, statistically in agreement with the present 
study (for asymptomatic parasitemia efficacy was O%, 
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for symptomatic parasitemia efficacy was 9%, statistical 
power 95% probability of efficacy ~50%). Antibody 
levels to Asn-Ala-Asn-Pro did not correlate with 
incidence59. It is not clear to what extent two 
non-contiguous copies of (Asn-Ala-Asn-Pro) in SPf66 
contributed to immunogenicity or efficacy. SPf66 was 
reported to be 55% effective (95% conficence interval 
21-75%) with blood slides made every 4-S weeks, in 
Venezuela6’, also statistically consistent with the present 
study (for asymptomatic parasitemia efficacy was O%, 
for symptomatic parasitemia efficacy was 9%, statistical 
power 95% probability of efficacy ~50%). SPf66 was 
reported to be 31% effective (95% conficence interval 
O-52%), with blood slides made only if temperature was 
37.5”, in Tanzania6’, also statistically consistent with the 
present study (for asymptomatic parasitemia efficacy 
was O%, for symptomatic parasitemia efficacy was 9%, 
statistical power 95% probability of efficacy ~50%). In 
the present study, visits to ascertain symptoms were 
made every day rather than waiting for patients to 
present, and blood slides were made every 1 week rather 
than every 4-8 weeks, and with such frequent active 
seeking the observation remains that every volunteer of 
both vaccine and control groups had a parastiemia at 
least once, and both vaccine and control groups had 
similar incidences of symptomatic parasitemia. 
The SPf66 vaccine was tested in the Gambia and 
found to have a protective efficacy of 8% (95% con- 
fidence interval - 18%29%, P=0.50)62, in statistical 
agreement with the present study showing protective 
efficacy against symptomatic parasitemia of 9% (statisti- 
cal power 95% probability of efficacy <50%), and also in 
statistical agreement with the study in Tanzania showing 
protective efficacy of 31% (95% conficence interval 
O-52%)61. 
With R32LR, in an immunigenicity study in semi- 
immune volunteers, with vaccination at 0, 8 and 16 
weeks, in Thailand, anti-circumsporozoite antibodies 
rose significantly, but fe1163. Minimal rainfall precluded 
natural malaria challenge, leaving the question of 
vaccine efficacy unresolved in that study62. 
Newer candidate vaccines may induce both humoral 
and cellular immunity, with better adjuvants, presenta- 
tion and delivery of antigens against multiple parasite 
stages. 
This present study in malaria-endemic semi-immune 
volunteers was useful for comparison with studies in 
animals and non-immune volunteers, in the absence of 
definitive laboratory assays of protective immunity. It 
showed that high levels of anti-circumsporozoite repeat 
antibody, induced by this antigen, with this adjuvant, 
were ineffective in preventing malaria in this endemic 
population, exposed to a range of intensity of natural 
challenge. 
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